For the quarter ending 2025-09-30, VTVT had $72,582K increase in cash & cash equivalents over the period.
| Cash Flow | 2025-09-30 | 2025-06-30 |
|---|---|---|
| Net loss before noncontrolling interest | -10,345 | -13,597 |
| Depreciation expense | 2 | 12 |
| Share-based compensation expense | 1,007 | 1,743 |
| Change in fair value of warrants-Related Party | 6 | -26 |
| Change in fair value of warrants-Nonrelated Party | 34 | 5 |
| Prepaid expenses | 481 | -833 |
| Other current assets | 19 | -82 |
| Other assets | -34 | -67 |
| Accounts payable and accrued expenses | 4,587 | 189 |
| Other liabilities | -47 | -90 |
| Net cash used in operating activities | -5,222 | -10,782 |
| Proceeds from sale of class a common stock, pre-funded and common warrants, net of offering costs | 77,476 | - |
| Proceeds from sale of class a common stock and pre-funded warrants, net of offering costs | 0 | 0 |
| Proceeds from issuance of class a common stock, net of offering costs | 0 | - |
| Proceeds from the exercise of stock options | 0 | 9 |
| Taxes paid related to net share settlement of equity awards | 0 | 51 |
| Proceeds from debt issuance | 392 | - |
| Repayment of notes payable | 64 | 0 |
| Net cash provided by financing activities | 77,804 | -42 |
| Net increase in cash and cash equivalents | 72,582 | -10,824 |
| Cash and cash equivalents at beginning of period | 36,746 | - |
| Cash and cash equivalents at end of period | 98,504 | - |
vTv Therapeutics Inc. (VTVT)
vTv Therapeutics Inc. (VTVT)